Intrinsic Capital Partners led a $12m Series A funding round in Nalu Bio.

Intrinsic Capital Partners, an investment firm, led a $12m Series A funding round in Nalu Bio, a producer of chemistry-based, ultra-pure cannabinoids, with participation from Flybridge Capital Partners, Portfolia Active Aging & Longevity Fund, Bonaventure Equity, L37 Ventures, Golden Seeds, Sacramento Angels, Brown Angel Group, and Axial Venture. "At Nalu Bio, we have created a platform that produces ultra-pure, cost-effective, non-hemp derived cannabinoids so that consumers and companies will have safer, more reliable products that improve everyday life. Intrinsic's belief in our chemistry-based approach and their leadership investing in cannabinoids and life sciences make them the ideal partner for us. This investment allows us to aggressively expand the business world-wide, own the category and bring high quality cannabinoids to manufacturers who want cost-effective THC-free ingredients for their products," Caitlyn Krebs, Nalu Bio Co-Founder and CEO.